Vivani Medical, Inc. (VANIW) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Vivani Medical, Inc. (VANIW) trades at $0.0101. Vivani Medical, Inc. is a clinical-stage company focused on developing miniature drug implants and implantable visual prostheses. Market cap: $3.36M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for VANIW: VANIW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VANIW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on VANIW.
How is this calculated? →Vivani Medical, Inc. (VANIW) Healthcare & Pipeline Overview
Vivani Medical, Inc., a clinical-stage medical device company, focuses on developing miniature drug implants and visual prostheses to treat chronic diseases and restore vision. With a portfolio of innovative implants, Vivani aims to provide minimally fluctuating drug profiles and artificial vision solutions in the healthcare sector.
What Is the Investment Thesis for VANIW?
Vivani Medical presents a high-risk, high-reward investment opportunity typical of clinical-stage medical device companies. The company's focus on implantable drug delivery systems and visual prostheses addresses significant unmet needs in the healthcare sector. Key value drivers include successful clinical trial outcomes and regulatory approvals for its lead products. The company's market capitalization is $0.00B, and it has a P/E ratio of -2.78. Upcoming clinical trial results will be a critical catalyst. However, potential risks include clinical trial failures, regulatory hurdles, and the need for additional funding. The company's ability to secure partnerships and navigate the regulatory landscape will be crucial for its long-term success.
Based on FMP financials and quantitative analysis
VANIW Key Highlights
Vivani Medical is a clinical-stage company focused on implantable medical devices.
- The company develops miniature drug implants for chronic diseases.
- Vivani Medical is also developing implantable visual prostheses for blind individuals.
- The company's headquarters are located in Emeryville, California.
- Vivani Medical has 50 employees.
Who Are VANIW's Competitors?
VANIW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VANIW's Key Strengths?
Innovative implantable medical device technology.
- Focus on unmet medical needs in chronic diseases and vision restoration.
- Potential for long-term drug delivery and improved patient outcomes.
- Experienced management team with expertise in medical device development.
What Are VANIW's Weaknesses?
Clinical-stage company with no currently approved products.
- Reliance on successful clinical trial outcomes and regulatory approvals.
- Limited financial resources and potential need for additional funding.
- High risk associated with medical device development and commercialization.
What Could Drive VANIW Stock Higher?
Clinical trial results for lead drug implant candidate in Q4 2026.
- FDA regulatory submission for visual prostheses device in Q2 2027.
- Development of new implantable medical device technologies.
- Expansion of strategic partnerships with pharmaceutical companies.
- Securing additional funding through grants or private placements.
What Are the Key Risks for VANIW?
Financial-distress signal — its Altman Z-Score of -5.98 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures or unexpected adverse events.
- Regulatory delays or rejection of product approvals.
- Competition from established medical device companies.
- Limited financial resources and need for additional funding.
- Dependence on key personnel and strategic partnerships.
What Are the Growth Opportunities for VANIW?
- Expansion into New Therapeutic Areas: Vivani Medical has the opportunity to leverage its implant technology platform to develop treatments for additional chronic diseases beyond its current focus. This could involve expanding into areas such as pain management, cardiovascular disease, or neurological disorders. The market for chronic disease management is substantial, with significant unmet needs and a growing aging population. Successful expansion into new therapeutic areas could significantly increase Vivani Medical's market potential and revenue streams.
- Strategic Partnerships and Collaborations: Forming strategic partnerships with pharmaceutical companies or other medical device manufacturers can accelerate the development and commercialization of Vivani Medical's products. Collaborations can provide access to additional funding, expertise, and distribution channels. For example, partnering with a pharmaceutical company could facilitate the development of drug-device combination products. These partnerships can reduce risk and accelerate market entry, enhancing Vivani Medical's competitive position.
- Geographic Expansion: Vivani Medical can expand its market reach by entering new geographic markets. Initially focusing on the US market, the company can then expand into Europe and other regions with established regulatory pathways for medical devices. International expansion requires navigating different regulatory requirements and healthcare systems, but it can significantly increase the company's potential customer base and revenue. This expansion should be carefully planned and executed to ensure compliance and market penetration.
- Advancements in Visual Prosthetics Technology: Continued research and development in visual prosthetics technology can lead to more advanced and effective devices. This includes improving the resolution, functionality, and biocompatibility of the implants. Breakthroughs in visual prosthetics could significantly improve the quality of life for blind individuals and create a substantial market opportunity for Vivani Medical. Investment in R&D is crucial for maintaining a competitive edge in this emerging field.
- Regulatory Approvals and Reimbursement: Securing regulatory approvals from agencies such as the FDA and obtaining favorable reimbursement policies from healthcare payers are critical for the commercial success of Vivani Medical's products. Successful navigation of the regulatory landscape and securing reimbursement coverage can drive adoption by healthcare providers and patients. This requires demonstrating the safety, efficacy, and cost-effectiveness of the company's products through clinical trials and health economic studies.
What Are VANIW's Competitive Advantages?
- Proprietary implant technology with patents.
- Focus on specialized areas with high barriers to entry.
- Clinical trial data demonstrating safety and efficacy.
- Strategic partnerships with key players in the healthcare industry.
What Does VANIW Do?
Vivani Medical, Inc. is a clinical-stage company dedicated to the development of innovative implantable medical devices. The company focuses on addressing chronic diseases with high unmet medical needs and restoring sight to blind individuals. Vivani Medical is developing a portfolio of miniature drug implants designed to deliver consistent and minimally fluctuating drug profiles, aiming to improve patient outcomes and adherence. Additionally, the company is working on implantable visual prostheses devices intended to provide useful artificial vision to blind individuals, potentially transforming their quality of life. Headquartered in Emeryville, California, Vivani Medical is committed to research and development in the medical device field. The company's focus on implantable technologies reflects a strategic approach to providing long-term therapeutic solutions. As a clinical-stage company, Vivani Medical is actively involved in clinical trials to evaluate the safety and efficacy of its products. The company currently has 50 employees. Vivani Medical's approach involves creating innovative solutions that can significantly impact patients' lives by addressing critical medical needs through advanced implant technology. The company operates within the medical device industry, focusing on specialized areas such as drug delivery systems and visual prosthetics.
What Products and Services Does VANIW Offer?
- Develop miniature drug implants for chronic diseases.
- Create implantable visual prostheses for blind individuals.
- Design implants to deliver minimally fluctuating drug profiles.
- Conduct clinical trials to evaluate the safety and efficacy of their products.
- Focus on addressing unmet medical needs in chronic disease management.
- Research and develop advanced implantable medical devices.
How Does VANIW Make Money?
- Develop and patent innovative implantable medical devices.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approvals from agencies like the FDA.
- Commercialize products through direct sales or partnerships.
What Industry Does VANIW Operate In?
Vivani Medical operates in the medical device industry, a sector characterized by innovation and stringent regulatory requirements. The market for implantable drug delivery systems is growing, driven by the need for improved patient adherence and therapeutic outcomes. The visual prosthetics market is also emerging, with potential to restore vision to individuals with certain types of blindness. Competition includes established medical device companies and other emerging players focused on similar technologies. Vivani Medical's success will depend on its ability to navigate the regulatory landscape, secure funding, and demonstrate clinical efficacy.
Who Are VANIW's Key Customers?
- Patients with chronic diseases requiring long-term drug delivery.
- Blind individuals seeking to restore vision.
- Healthcare providers and hospitals using implantable devices.
- Pharmaceutical companies interested in drug-device combination products.
Company Profile
Vivani Medical, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO Adam Mendelsohn.
Financial Health
Vivani Medical, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.98 places it in the distress zone, a signal of elevated financial risk.
VANIW Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in the potential growth of Vivani Medical.
- Community sentiment has shifted positively, with discussions highlighting the innovative approach to diabetes management, attracting interest from health-focused investors.
- The company's recent partnerships with healthcare providers have been well-received, enhancing its credibility and market presence.
- Positive news coverage regarding advancements in their product pipeline has generated optimism among investors, leading to increased social media engagement.
Bear Case
- Concerns about regulatory hurdles remain prevalent, as the approval process for medical devices can be lengthy and unpredictable, causing investor anxiety.
- Recent bearish sentiment in the healthcare sector may impact Vivani's stock performance, as broader market trends often influence individual companies.
- Some community members express skepticism about the scalability of Vivani's technology, questioning whether it can capture significant market share in a competitive landscape.
- A lack of recent financial disclosures has led to uncertainty among investors, with many feeling uninformed about the company's current financial health.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VANIW Latest News
No recent news available for VANIW.
VANIW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VANIW.
Price Targets
Wall Street price target analysis for VANIW.
VANIW MoonshotScore
What does this score mean?
The MoonshotScore rates VANIW 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Adam Mendelsohn
CEO
Adam Mendelsohn is the CEO of Vivani Medical, Inc. He is responsible for managing the company's operations and strategic direction. His background includes experience in the healthcare and medical device industries. Adam oversees a team of 50 employees and is focused on advancing the company's pipeline of implantable medical devices. His leadership is crucial for navigating the challenges of clinical development and regulatory approval.
Track Record: As CEO, Adam Mendelsohn is focused on guiding Vivani Medical through clinical trials and towards potential commercialization of its products. His strategic decisions are centered on securing funding, building partnerships, and achieving key milestones in the development of the company's drug implants and visual prostheses. His success will be measured by the company's ability to obtain regulatory approvals and bring innovative medical devices to market.
VANIW OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Vivani Medical may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Potential for price manipulation and fraud.
- Higher risk of delisting or going out of business.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Understand the company's capital structure and funding needs.
- Monitor news and developments related to the company and its industry.
- Experienced management team with relevant industry expertise.
- Proprietary technology and patent portfolio.
- Ongoing clinical trials and research activities.
- Partnerships with reputable healthcare organizations.
- Clear business plan and strategic objectives.
Vivani Medical, Inc. Healthcare Stock: Key Questions Answered
What does Vivani Medical, Inc. do?
Vivani Medical, Inc. is a clinical-stage company focused on developing implantable medical devices. The company is developing miniature drug implants designed to deliver consistent drug profiles for treating chronic diseases. Additionally, Vivani Medical is working on implantable visual prostheses intended to provide artificial vision to blind individuals. The company's goal is to address unmet medical needs through innovative implantable technologies.
What do analysts say about VANIW stock?
As of March 18, 2026, there is no readily available analyst consensus on Vivani Medical (VANIW) due to its OTC listing and clinical-stage nature. Key valuation metrics are difficult to assess given the lack of revenue and earnings. Investors should focus on monitoring clinical trial results, regulatory milestones, and the company's ability to secure funding. The stock is highly speculative and carries significant risk.
What are the main risks for VANIW?
The main risks for Vivani Medical include the potential for clinical trial failures, regulatory hurdles, and competition from established medical device companies. As a clinical-stage company, Vivani Medical is heavily reliant on the successful development and approval of its products. The company also faces financial risks, as it requires significant funding to support its research and development activities.
What are the key growth opportunities for VANIW in healthcare?
Vivani Medical, Inc.'s growth opportunities lie in expanding its implantable technology platform to new therapeutic areas beyond its current focus. This includes exploring applications in pain management, neurological disorders, and cardiovascular diseases. Geographic expansion into European and Asian markets also presents a significant growth opportunity. Furthermore, strategic partnerships with pharmaceutical companies can accelerate the development and commercialization of its products.
What is Vivani Medical, Inc.'s drug pipeline status?
Vivani Medical, Inc. is currently in the clinical stage, with its lead drug implant candidate undergoing clinical trials. The company is also advancing the development of its implantable visual prostheses device. Specific details regarding the clinical pipeline stages, therapeutic areas, and upcoming catalysts are not publicly available. Investors should monitor the company's press releases and SEC filings (if any) for updates on its clinical development programs.
What are the key factors to evaluate for VANIW?
Evaluate VANIW on fundamentals, analyst consensus, and risk factors. Vivani Medical presents a high-risk, high-reward investment opportunity typical of clinical-stage medical device companies. Not financial advice.
How frequently does VANIW data refresh on this page?
VANIW's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VANIW's recent stock price performance?
Vivani Medical, Inc. (VANIW) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative implantable medical device technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be limited due to the company's OTC listing and clinical-stage nature.
- AI analysis is pending and may provide additional insights in the future.